$3.29
-0.07[-2.08%]
At close: Apr 5
$3.29
0[0.00%]
After Hours: 4:48PM EDT
Acasti Pharma
(NASDAQ:ACST)Acasti Pharma Stock (NASDAQ:ACST), Analyst Ratings, Price Targets, Predictions
Acasti Pharma Inc has a consensus price target of $4.22, established from looking at the 6 latest analyst ratings. The last 3 analyst ratings were released from Craig-Hallum, EF Hutton, and EF Hutton on February 7, 2024, February 15, 2023, and December 19, 2022. With an average price target of $3.67 between Craig-Hallum, EF Hutton, and EF Hutton, there's an implied 11.45% upside for Acasti Pharma Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Craig-Hallum
EF Hutton
HC Wainwright & Co.
Oppenheimer
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Acasti Pharma
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 02/07/2024 | ACST | Buy Now | Acasti Pharma | $3.29 | 82.37% | Craig-Hallum | Chase Knickerbocker | → $6 | Initiates | → Buy | Get Alert |
| 02/15/2023 | ACST | Buy Now | Acasti Pharma | $3.29 | -24.01% | EF Hutton | Constantine Davides | → $15 | Reiterates | → Buy | Get Alert |
| 12/19/2022 | ACST | Buy Now | Acasti Pharma | $3.29 | -24.01% | EF Hutton | Constantine Davides | → $15 | Initiates | → Buy | Get Alert |
| 12/15/2022 | ACST | Buy Now | Acasti Pharma | $3.29 | -27.05% | HC Wainwright & Co. | Oren Livnat | → $14.4 | Initiates | → Buy | Get Alert |
| 12/22/2021 | ACST | Buy Now | Acasti Pharma | $3.29 | 82.37% | Oppenheimer | Leland Gershell | → $36 | Initiates | → Outperform | Get Alert |
| 12/21/2021 | ACST | Buy Now | Acasti Pharma | $3.29 | 82.37% | Oppenheimer | Leland Gershell | → $36 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Acasti Pharma (ACST)?
The latest price target for Acasti Pharma (NASDAQ: ACST) was reported by Craig-Hallum on February 7, 2024. The analyst firm set a price target for $6.00 expecting ACST to rise to within 12 months (a possible 82.37% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Acasti Pharma (ACST)?
The latest analyst rating for Acasti Pharma (NASDAQ: ACST) was provided by Craig-Hallum, and Acasti Pharma initiated their buy rating.
When was the last upgrade for Acasti Pharma (ACST)?
There is no last upgrade for Acasti Pharma.
When was the last downgrade for Acasti Pharma (ACST)?
There is no last downgrade for Acasti Pharma.
When is the next analyst rating going to be posted or updated for Acasti Pharma (ACST)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acasti Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acasti Pharma was filed on February 7, 2024 so you should expect the next rating to be made available sometime around February 7, 2025.
Is the Analyst Rating Acasti Pharma (ACST) correct?
While ratings are subjective and will change, the latest Acasti Pharma (ACST) rating was a initiated with a price target of $0.00 to $6.00. The current price Acasti Pharma (ACST) is trading at is $3.29, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.